A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Phase 3
530
about 3.3 years
18–80
74 sites in AL, AZ, CA +24
What this study is about
Researchers are testing whether risankizumab or vedolizumab are effective treatments for adults with moderate to severe ulcerative colitis who haven't received targeted therapies before. The trial will last about 69 weeks, and participants will receive either risankizumab (IV then subcutaneous) or vedolizumab (IV throughout).
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Risankizumab
- 2.Take Vedolizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
risankizumab, vedolizumab
injection, intravenous
Gastroenterology